Drug Trial Radar · NCT05484206
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Sep 21, 2022
Primary completion
Dec 9, 2025
Study completion Dec 9, 2025
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Conditions
- Hepatic Impairment
- Cirrhosis
Interventions
VIR-2218Drug
VIR-2218 given by subcutaneous injection.
VIR-3434Drug
VIR-3434 given by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218Time frame: 5 days
- Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR2218Time frame: 5 days
- Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR2218Time frame: 5 days
- Maximum observed Plasma concentration (Cmax) of VIR-3434Time frame: 18 weeks
- Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-3434Time frame: 18 weeks
- Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-3434Time frame: 18 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Inland Empire Clinical Trials
Rialto, California
Orange County Research Center
Tustin, California
Floridian Clinical Research
Miami Lakes, Florida
Texas Liver Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.